NATCO Pharma Limited
NSE: NATCOPHARMMarket Closed • NSE
Day range
52 week range
NATCO Pharma Limited closed at INR785.05 (+0.01%) on volume 1.05x its 20-day average, trading 36.01% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -23.4% QoQ
2026-10-01
RIGHTS Announced
Rights 2:21 @ Premium Rs 748/-
2026-08-20
DIVIDEND Announced
Interim Dividend - Rs 1.50 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Strong Capital Efficiency: ROCE stands at 17.4%
Low Debt Profile: Debt-to-Equity is comfortable at 0.08x
High Cash Flow Conversion: CFO/PAT averaged 1.11x over last 3 years
Attractive Valuation: P/E of 12.4x trades below sector historical averages
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 01 Oct 2026 | Rights issue | Rights 2:21 @ Premium Rs 748/- | — | 01 Oct 2026 |
| 20 Aug 2026 | Dividend | ₹1.50 / share | — | 20 Aug 2026 |
| 18 Feb 2026 | Dividend | ₹1.50 / share | — | 18 Feb 2026 |
| 20 Nov 2025 | Dividend | ₹1.50 / share | — | 20 Nov 2025 |
| 19 Aug 2025 | Dividend | ₹2.00 / share | — | 19 Aug 2025 |
| 18 Feb 2025 | Dividend | ₹1.50 / share | — | 18 Feb 2025 |
| 27 Nov 2024 | Dividend | ₹1.50 / share | — | 27 Nov 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 25 Sept 2024 |
| 23 Aug 2024 | Dividend | ₹3.00 / share | — | 23 Aug 2024 |
| 26 Feb 2024 | Dividend | ₹1.25 / share | — | 26 Feb 2024 |
| 24 Nov 2023 | Dividend | ₹1.25 / share | — | 24 Nov 2023 |
| — | Annual General Meeting | Annual General Meeting | — | 25 Sept 2023 |
| 22 Aug 2023 | Dividend | ₹7.00 / share | — | 22 Aug 2023 |
| 21 Feb 2023 | Dividend | ₹1.25 / share | — | 21 Feb 2023 |
| 22 Nov 2022 | Dividend | ₹0.75 / share | — | 21 Nov 2022 |
| — | Annual General Meeting | Annual General Meeting | — | 23 Sept 2022 |
| 22 Aug 2022 | Dividend | ₹3.50 / share | — | 19 Aug 2022 |
| 25 Feb 2022 | Dividend | ₹2.00 / share | — | 24 Feb 2022 |
| 24 Nov 2021 | Dividend | ₹0.50 / share | — | 23 Nov 2021 |
| — | Annual General Meeting | Annual General Meeting | — | 23 Sept 2021 |
| 25 Aug 2021 | Dividend | ₹2.00 / share | — | 24 Aug 2021 |
| 23 Feb 2021 | Dividend | ₹1.00 / share | — | 22 Feb 2021 |
| 25 Nov 2020 | Dividend | ₹3.00 / share | — | 24 Nov 2020 |
| — | Annual General Meeting | Annual General Meeting | — | 09 Oct 2020 |
| 24 Aug 2020 | Dividend | ₹1.25 / share | — | 21 Aug 2020 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. [1] NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.[2]
IndiaHealthcare
Is NATCO Pharma Limited Shariah compliant?
NATCO Pharma Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (4.94%) complies with AAOIFI threshold (≤ 33%).
What is NATCO Pharma Limited's current valuation relative to peers?
NATCO Pharma Limited trades at a P/E of 12.4x compared to the sector median of 37x, and a Price-to-Book of 1.5x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.08x. Interest coverage is 33.5x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 0.5% while net profit growth averaged 0.4%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.